Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia

Share this page:

Title

Subject

Description

The use of high-dose intravenous immune globulin (IVIG) plus anticoagulation is recommended for the treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare side effect of adenoviral vector vaccines against coronavirus disease 2019 (Covid-19).

Creator

Date Last Updated (Year-Month-Day)

2021-08-19

Type

Publication

Citation

Bourguignon, Alex, Donald M. Arnold, Theodore E. Warkentin, James W. Smith, Tania Pannu, Jeffrey M. Shrum, Zainab A. A. Al Maqrashi, Anjali Shroff, Marie-Claude Lessard, Normand Blais, John G. Kelton, and Ishac Nazy. 2021. "Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia." New England Journal of Medicine 385 (8):720-8.

Accessibility

Free online on NEJM.

URL

https://www.nejm.org/doi/full/10.1056/NEJMoa2107051

Read Online

https://www.nejm.org/doi/full/10.1056/NEJMoa2107051

Click for External Resource

https://www.nejm.org/doi/full/10.1056/NEJMoa2107051

*This link may link to a hosted zip file or an external resource. Zip files will download automatically. Other links will open in a new window.

Item Type:

Publication

Collection

Discover

Citation for this page

Bourguignon, Alex, Donald M. Arnold, Theodore E. Warkentin, James W. Smith, Tania Pannu, Jeffrey M. Shrum, Zainab A. A. Al Maqrashi, Anjali Shroff, Marie-Claude Lessard, Normand Blais, John G. Kelton, and Ishac Nazy. , “Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia,” NETEC Resource Library, accessed September 18, 2021, https://repository.netecweb.org/items/show/1614.

Terms of Use

By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.